These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31996575)

  • 1. Clinical Practice Guideline for Complex Attention Deficit Hyperactivity Disorder Supplement: A note from the Editor-in-Chief.
    Pachter LM
    J Dev Behav Pediatr; 2020; 41 Suppl 2S():S32. PubMed ID: 31996575
    [No Abstract]   [Full Text] [Related]  

  • 2. Managing attention-deficit/hyperactivity disorder in primary care: a systematic analysis of roles and challenges.
    Power TJ; Mautone JA; Manz PH; Frye L; Blum NJ
    Pediatrics; 2008 Jan; 121(1):e65-72. PubMed ID: 18166546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does collateral retrospective information about childhood attention-deficit/hyperactivity disorder symptoms assist in the diagnosis of attention-deficit/hyperactivity disorder in adults? Findings from a large clinical sample.
    Breda V; Rovaris DL; Vitola ES; Mota NR; Blaya-Rocha P; Salgado CA; Victor MM; Picon FA; Karam RG; Silva KL; Rohde LA; Bau CH; Grevet EH
    Aust N Z J Psychiatry; 2016 Jun; 50(6):557-65. PubMed ID: 26460329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents with Complex Attention-Deficit/Hyperactivity Disorder: Process of Care Algorithms.
    Barbaresi WJ; Campbell L; Diekroger EA; Froehlich TE; Liu YH; O'Malley E; Pelham WE; Power TJ; Zinner SH; Chan E
    J Dev Behav Pediatr; 2020; 41 Suppl 2S():S58-S74. PubMed ID: 31996578
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting.
    Hamilton RM; Rosenthal E; Hulpke-Wette M; Graham JG; Sergeant J;
    Cardiol Young; 2012 Feb; 22(1):63-70. PubMed ID: 21771383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attention deficit hyperactivity disorder in adults: what the non-specialist needs to know.
    Johnson J; Morris S; George S
    Br J Hosp Med (Lond); 2020 Mar; 81(3):1-11. PubMed ID: 32240011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attention-deficit/hyperactivity disorder: etiology and pharmacotherapy.
    Noorbala AA; Akhondzadeh S
    Arch Iran Med; 2006 Oct; 9(4):374-80. PubMed ID: 17061613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder.
    Visser SN; Lesesne CA; Perou R
    Pediatrics; 2007 Feb; 119 Suppl 1():S99-106. PubMed ID: 17272592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. To the editor: efficacy of oral iron for the treatment of attention deficit hyperactivity disorder in children with low ferritin levels.
    Poulton A
    Pediatr Neurol; 2008 Jul; 39(1):74; author reply 74. PubMed ID: 18555182
    [No Abstract]   [Full Text] [Related]  

  • 10. Predicting substance use disorder using long-term attention deficit hyperactivity disorder medication records in Truven.
    Fouladvand S; Hankosky ER; Bush H; Chen J; Dwoskin LP; Freeman PR; Henderson DW; Kantak K; Talbert J; Tao S; Zhang GQ
    Health Informatics J; 2020 Jun; 26(2):787-802. PubMed ID: 31106686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine Treatment Strengthens an Anti-Correlated Relationship between Functional Brain Networks in Medication-Naïve Adults with Attention-Deficit Hyperactivity Disorder: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
    Lin HY; Gau SS
    Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv094. PubMed ID: 26377368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychopharmacotherapy of Attention Deficit-Hyperactivity Disorder in Children with Comorbid Conditions.
    Naguy A
    Pediatr Neurol; 2018 May; 82():7-12. PubMed ID: 29678368
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Veluri N; Patel RS
    J Child Adolesc Psychopharmacol; 2021 May; 31(4):324-326. PubMed ID: 34014772
    [No Abstract]   [Full Text] [Related]  

  • 15. [Atomoxetine Treatment For Encopresis In A Child With Attention Deficit Hyperactivity Disorder].
    Bozkurt H; Şahin S
    Turk Psikiyatri Derg; 2016; 27(2):0. PubMed ID: 27482753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attention Deficit Hyperactivity Disorder in Preschool-Age Children.
    Tandon M; Pergjika A
    Child Adolesc Psychiatr Clin N Am; 2017 Jul; 26(3):523-538. PubMed ID: 28577607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of memantine in adult patients with attention deficit hyperactivity disorder.
    Mohammadzadeh S; Ahangari TK; Yousefi F
    Hum Psychopharmacol; 2019 Jan; 34(1):e2687. PubMed ID: 30663824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing attention deficit hyperactivity disorder in adults using illicit psychostimulants: A systematic review.
    Cook J; Lloyd-Jones M; Arunogiri S; Ogden E; Bonomo Y
    Aust N Z J Psychiatry; 2017 Sep; 51(9):876-885. PubMed ID: 28639480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].
    Akhondzadeh S; Mohammadi MR; Khademi M
    BMC Psychiatry; 2004 Apr; 4():9. PubMed ID: 15070418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supplementary guanfacine hydrochloride as a treatment of attention deficit hyperactivity disorder in adults: A double blind, placebo-controlled study.
    Butterfield ME; Saal J; Young B; Young JL
    Psychiatry Res; 2016 Feb; 236():136-141. PubMed ID: 26730446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.